Kolodych S et al. |
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. |
2017 |
Eur J Med Chem |
pmid:28818506
|
Cruz-Monserrate Z et al. |
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. |
2003 |
Eur. J. Biochem. |
pmid:12950266
|
Thery JC et al. |
Resistance to human epidermal growth factor receptor type 2-targeted therapies. |
2014 |
Eur. J. Cancer |
pmid:24462377
|
Schatten G and Schatten H |
Effects of motility inhibitors during sea urchin fertilization: microfilament inhibitors prevent sperm incorporation and restructuring of fertilized egg cortex, whereas microtubule inhibitors prevent pronuclear migrations. |
1981 |
Exp. Cell Res. |
pmid:7308293
|
Schrek R and Stefani SS |
Toxicity of microtubular drugs to leukemic lymphocytes. |
1981 |
Exp. Mol. Pathol. |
pmid:7238845
|
Suwanborirux K et al. |
Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. |
1990 |
Experientia |
pmid:2298279
|
Van den Mooter T et al. |
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2015 |
Expert Opin Biol Ther |
pmid:25865453
|
Dirix LY et al. |
Trastuzumab emtansine in breast cancer. |
2013 |
Expert Opin Biol Ther |
pmid:23477731
|
Bergamini A et al. |
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. |
2016 |
Expert Opin Investig Drugs |
pmid:27797594
|
Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Cho WC and Roukos DH |
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. |
2013 |
Expert Rev Anticancer Ther |
pmid:23259420
|
Sapra P et al. |
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. |
2013 |
Expert Rev Clin Pharmacol |
pmid:23978126
|
Miranda Romero P and MarÃn Gil R |
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. |
2015 |
Farm Hosp |
pmid:26005893
|
Bhattacharyya B and Wolff J |
Maytansine binding to the vinblastine sites of tubulin. |
1977 |
FEBS Lett. |
pmid:852577
|
Yap LW et al. |
Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. |
2017 |
Fetal Pediatr Pathol |
pmid:27935326
|
Eckelmann D et al. |
Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. |
2017 |
Fitoterapia |
pmid:28385670
|
Eckelmann D et al. |
Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. |
2016 |
Fitoterapia |
pmid:27521896
|
Berdeja JG |
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. |
2014 |
Front Biosci (Landmark Ed) |
pmid:24389179
|
Lianos GD and Roukos DH |
From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. |
2014 |
Future Oncol |
pmid:24490597
|
Moore KN et al. |
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29424243
|
Doroshow DB and LoRusso PM |
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. |
2018 |
Future Oncol |
pmid:29214842
|
Fabi A et al. |
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? |
2017 |
Future Oncol |
pmid:29182361
|
Moore KN et al. |
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29098867
|
Peddi PF and Hurvitz SA |
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. |
2013 |
Future Oncol |
pmid:23469968
|
Chu YW and Polson A |
Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. |
2013 |
Future Oncol |
pmid:23469971
|
Bighin C et al. |
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. |
2013 |
Future Oncol |
pmid:23837759
|
Ono Y et al. |
Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. |
1982 |
Gan |
pmid:6186564
|
Tsuruo T et al. |
Establishment and properties of vincristine-resistant human myelogenous leukemia K562. |
1983 |
Gan |
pmid:6580255
|
Yabe N et al. |
[A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. |
2015 |
Gan To Kagaku Ryoho |
pmid:26805183
|
Noguchi E and Shimizu C |
[T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. |
2013 |
Gan To Kagaku Ryoho |
pmid:23306913
|
Boku N |
HER2-positive gastric cancer. |
2014 |
Gastric Cancer |
pmid:23563986
|
Coussy F et al. |
[New targeted therapies in breast cancer]. |
2014 |
Gynecol Obstet Fertil |
pmid:25442825
|
Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Menderes G et al. |
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. |
2017 |
Gynecol. Oncol. |
pmid:28705408
|
Menderes G et al. |
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. |
2017 |
Gynecol. Oncol. |
pmid:28473206
|
Teplinsky E and Muggia F |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions. |
2014 |
Gynecol. Oncol. |
pmid:25220628
|
Martin LP et al. |
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. |
2017 |
Gynecol. Oncol. |
pmid:28843653
|
Carvajal-Hausdorf DE et al. |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. |
2017 |
Gynecol. Oncol. |
pmid:28196634
|
|
Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. |
2012 |
Harv Health Lett |
pmid:23243689
|
Drachman JG and Senter PD |
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. |
2013 |
Hematology Am Soc Hematol Educ Program |
pmid:24319196
|
Yeo W et al. |
Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2018 |
Hong Kong Med J |
pmid:29326401
|
Damodaran S and Olson EM |
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. |
2012 |
Hosp Pract (1995) |
pmid:23299030
|
Watanabe J et al. |
Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. |
|
In Vivo |
pmid:28438884
|
Madden R et al. |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. |
2018 |
Int J Clin Pharmacol Ther |
pmid:29231164
|
Janthur WD et al. |
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. |
2012 |
Int J Mol Sci |
pmid:23443108
|
Zhong P et al. |
αβ integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. |
2017 |
Int J Nanomedicine |
pmid:29138558
|
Li Y et al. |
EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. |
2017 |
Int J Nanomedicine |
pmid:28894364
|
Mang Y et al. |
Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. |
2015 |
Int. Immunopharmacol. |
pmid:25467246
|
Ladino CA et al. |
Folate-maytansinoids: target-selective drugs of low molecular weight. |
1997 |
Int. J. Cancer |
pmid:9399666
|
Kim SB et al. |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. |
2016 |
Int. J. Cancer |
pmid:27428671
|